Delcath Systems, Inc. DCTH

QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.

On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report […]

QUEENSBURY, N.Y., August 31, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected